Susquehanna International Group
NKTR icon

Susquehanna International Group’s Nektar Therapeutics NKTR Stock Holding History

Susquehanna International Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.9M Sell
221,100
-143,300
-39% -$8.16M ﹤0.01% 2499
2025
Q4 		$15.4M Sell
364,400
-183,800
-34% -$10.3M ﹤0.01% 2503
2025
Q3 		$31.2M Sell
548,200
-92,100
-14% -$3.05M ﹤0.01% 1755
2025
Q2 		$16.5M Buy
640,300
+638,467
+34,832% +$7.17M ﹤0.01% 2212
2025
Q1 		$18.7K Buy
+1,833
New +$23.9K ﹤0.01% 12127
2024
Q3 		– Sell
-2,460
Closed -$45.8K – 12676
2024
Q2 		$45.8K Buy
+2,460
New +$51.8K ﹤0.01% 11448
2022
Q4 		– Sell
-680
Closed -$33K – 13257
2022
Q3 		$33K Sell
680
-1,353
-67% -$80.5K ﹤0.01% 12412
2022
Q2 		$116K Sell
2,033
-44,000
-96% -$2.78M ﹤0.01% 11325
2022
Q1 		$3.72M Buy
46,033
+40,946
+805% +$6.06M ﹤0.01% 4219
2021
Q4 		$1.03M Sell
5,087
-2,180
-30% -$473K ﹤0.01% 7217
2021
Q3 		$1.96M Sell
7,267
-11,293
-61% -$2.72M ﹤0.01% 5880
2021
Q2 		$4.78M Buy
18,560
+13,053
+237% +$3.61M ﹤0.01% 4114
2021
Q1 		$1.65M Sell
5,507
-460
-8% -$143K ﹤0.01% 6389
2020
Q4 		$1.52M Sell
5,967
-2,300
-28% -$594K ﹤0.01% 5714
2020
Q3 		$2.06M Sell
8,267
-1,766
-18% -$555K ﹤0.01% 4565
2020
Q2 		$3.49M Buy
10,033
+1,920
+24% +$599K ﹤0.01% 3550
2020
Q1 		$2.17M Sell
8,113
-24,787
-75% -$7.67M ﹤0.01% 3822
2019
Q4 		$10.7M Sell
32,900
-19,247
-37% -$5.58M ﹤0.01% 2018
2019
Q3 		$14.2M Sell
52,147
-21,180
-29% -$7.77M ﹤0.01% 1624
2019
Q2 		$39.1M Buy
73,327
+11,300
+18% +$5.67M 0.01% 816
2019
Q1 		$31.3M Buy
62,027
+10,274
+20% +$6.09M 0.01% 898
2018
Q4 		$25.5M Sell
51,753
-147
-0.3% -$88.7K 0.01% 939
2018
Q3 		$47.5M Sell
51,900
-10,440
-17% -$8.91M 0.02% 736
2018
Q2 		$45.7M Buy
62,340
+18,053
+41% +$20.8M 0.02% 734
2018
Q1 		$70.6M Buy
44,287
+31,734
+253% +$40.9M 0.03% 519
2017
Q4 		$11.2M Buy
12,553
+1,493
+13% +$883K ﹤0.01% 1728
2017
Q3 		$3.98M Sell
11,060
-6,640
-38% -$2.08M ﹤0.01% 2811
2017
Q2 		$5.19M Buy
17,700
+7,193
+68% +$2.08M ﹤0.01% 2366
2017
Q1 		$3.7M Sell
10,507
-5,906
-36% -$1.33M ﹤0.01% 2714
2016
Q4 		$3.02M Buy
16,413
+8,513
+108% +$1.73M ﹤0.01% 3230
2016
Q3 		$2.04M Buy
7,900
+4,927
+166% +$1.27M ﹤0.01% 3542
2016
Q2 		$635K Sell
2,973
-2,187
-42% -$489K ﹤0.01% 5712
2016
Q1 		$1.06M Buy
5,160
+1,693
+49% +$325K ﹤0.01% 4962
2015
Q4 		$876K Sell
3,467
-613
-15% -$126K ﹤0.01% 5680
2015
Q3 		$671K Sell
4,080
-2,773
-40% -$491K ﹤0.01% 6547
2015
Q2 		$1.29M Sell
6,853
-1,347
-16% -$232K ﹤0.01% 5661
2015
Q1 		$1.35M Buy
8,200
+1,740
+27% +$358K ﹤0.01% 5146
2014
Q4 		$1.5M Sell
6,460
-1,447
-18% -$309K ﹤0.01% 5031
2014
Q3 		$1.43M Sell
7,907
-6,326
-44% -$1.21M ﹤0.01% 5225
2014
Q2 		$2.74M Sell
14,233
-854
-6% -$151K ﹤0.01% 4060
2014
Q1 		$2.74M Buy
15,087
+540
+4% +$107K ﹤0.01% 3793
2013
Q4 		$2.48M Sell
14,547
-3,780
-21% -$610K ﹤0.01% 3929
2013
Q3 		$2.87M Buy
18,327
+14,120
+336% +$2.61M ﹤0.01% 3552
2013
Q2 		$729K Buy
+4,207
New +$645K ﹤0.01% 5492

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Susquehanna International Group's NKTR Position: Q1 2026 in Review

Susquehanna International Group reduced its Nektar Therapeutics (NKTR) stake by 35% in Q1 2026, selling an estimated $7.64M and leaving 249,090 shares worth $17.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2368.

Susquehanna International Group first reported a position in NKTR in Q2 2013 and has held it in 49 quarters since. The position peaked at $64.8M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Susquehanna International Group held 249,090 shares of Nektar Therapeutics worth $17.9M as of Q1 2026.
  • Susquehanna International Group sold 134,220 Nektar Therapeutics shares in Q1 2026, an estimated $7.64M.
  • Nektar Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2368 holding.
  • Susquehanna International Group first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's Nektar Therapeutics position peaked at $64.8M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.